Brentuximab

Description

Brentuximab is a recombinant IgG1 kappa, humanized monoclonal antibody, targeting CD30. It is used for the synthesis of antibody-drug conjugates (ADC) drugs for various types of lymphoma treating.

Contact Us for a Quote!

Please enable JavaScript in your browser to complete this form.
Name

Data Gallery

Fig. 1.) 4-20% SDS-PAGE analysis
Recombinant protein was visualized by Coomassie Brilliant Blue R250 staining.

Fig. 2.)    SEC-HPLC analysis
Column: Superdex 200 Increase 5/150 GL
Running buffer: 2xPBS, pH 7.4